Company Performance - Myomo, Inc. reported a quarterly loss of $0.03 per share, better than the Zacks Consensus Estimate of a loss of $0.04, and an improvement from a loss of $0.06 per share a year ago, representing an earnings surprise of 25% [1] - The company posted revenues of $9.21 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 15.82%, and up from $5.08 million in the same quarter last year [2] - Over the last four quarters, Myomo has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Outlook - Myomo shares have declined approximately 21% since the beginning of the year, contrasting with the S&P 500's gain of 21.2% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.01 on revenues of $9.45 million, and for the current fiscal year, it is -$0.18 on revenues of $28.62 million [7] - The estimate revisions trend for Myomo is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Products industry, to which Myomo belongs, is currently ranked in the top 36% of over 250 Zacks industries, suggesting that companies in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8]

Revenue Performance - Revenue for the third quarter of 2024 was $9.2 million, up 81% compared to the third quarter of 2023[2] - Product revenue increased 83% year-over-year, driven by a record 161 MyoPro units sold, up 35%[4] - Product revenue for the three months ended September 30, 2024, was $9,207,586, a 83.3% increase from $5,029,523 in the same period of 2023[19] - The company expects fourth quarter revenue to be in the range of $9.5 million to $10.5 million, raising full-year revenue guidance to $30 million to $31 million[11] Patient and Order Metrics - The patient pipeline reached 1,263 patients, an increase of 21% year-over-year, with 645 new candidates added in the third quarter, up 69%[9] - Backlog of orders and insurance authorizations was a record 316 units, up 71% compared to the same period last year[2] Financial Performance - Gross margin for the third quarter was 75.4%, an increase of 670 basis points from 68.7% in the same quarter of 2023[5] - Adjusted EBITDA for the third quarter was $(0.6) million, an improvement from $(1.7) million in the same quarter of 2023[8] - Net loss for the nine months ended September 30, 2024, was $5,923,648, compared to a net loss of $5,687,461 for the same period in 2023[22] - Adjusted EBITDA for the nine months ended September 30, 2024, was $(5,294,458), compared to $(4,886,541) for the same period in 2023[23] Operating Expenses - Operating expenses for the third quarter were $7.9 million, a 43% increase compared to the third quarter of 2023[6] - Operating expenses for the three months ended September 30, 2024, totaled $7,903,108, up from $5,513,217 in the same period of 2023, indicating a 43.4% increase[19] - Research and development expenses for the three months ended September 30, 2024, were $1,248,870, compared to $717,256 in the same period of 2023, reflecting a 74.1% increase[19] Cash and Assets - Cash, cash equivalents, and restricted cash as of September 30, 2024, were $7.0 million, with cash used in operating activities at $1.5 million for the third quarter[10] - Cash and cash equivalents at the end of the period were $6,997,675, slightly up from $6,911,747 at the end of the same period in 2023[22] - Total current assets increased to $14,704,144 as of September 30, 2024, from $13,650,983 at December 31, 2023, reflecting an 7.7% growth[21] - Total liabilities rose to $7,020,537 as of September 30, 2024, compared to $5,592,218 at December 31, 2023, marking a 25.5% increase[21] Shareholder Information - The company reported a weighted average number of common shares outstanding of 37,950,515 for the three months ended September 30, 2024, compared to 35,266,361 for the same period in 2023[19] Strategic Initiatives - The company launched its orthotics and prosthetics channel program in September 2024, aiming for growth in this area in 2025 and beyond[2]

Financial Data and Key Metrics Changes - Revenue for Q2 2024 was $7.5 million, up 77% year-over-year, with total revenue increasing by 26% compared to the same quarter last year [12][13] - Product revenue growth was driven by a 63% increase in revenue units and a higher average selling price (ASP) of approximately $47,500, up 9% year-over-year [13][14] - Gross margin for Q2 2024 was 70.8%, slightly down from 71.8% in the prior year, primarily due to the impact of high-margin license revenue in the previous year [17][18] - Operating loss for Q2 2024 was $1.1 million, unchanged from Q2 2023, while net loss was $1.1 million or $0.03 per share, compared to a net loss of $1 million or $0.04 per share in the prior year [19][20] Business Line Data and Key Metrics Changes - The company recognized revenue on 74 MyoPros delivered to Medicare Part B beneficiaries, contributing to a record number of patient pipeline additions and authorizations [6][7] - The patient pipeline reached 1,179 patients, with 550 additions in Q2, marking a 35% year-over-year increase [16] - Revenue from Medicare Advantage plans represented 26% of total revenue, down 26% year-over-year due to a more challenging reimbursement environment [14] Market Data and Key Metrics Changes - International operations, primarily in Germany, generated over $1 million in revenue during the quarter [10] - The company has seen a positive trend with some Medicare Advantage plans starting to remit payments at the Medicare rate, contributing to the higher ASP [9] Company Strategy and Development Direction - The company plans to expand its manufacturing capacity and is finalizing plans to move to a larger production facility in the Boston area [10][24] - There is a focus on building relationships with O&P clinics and training clinicians to become MyoPro centers of excellence, with a goal of training 80 to 100 clinicians by the end of the year [30][51] - Increased investment in R&D is planned to innovate product development and maintain a first-mover advantage in the market [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue growth in the third quarter, expecting revenue in the range of $8.0 million to $8.5 million, representing a year-over-year growth of 58% to 67% [22] - The company anticipates that the second half of the year will be stronger than the first half, historically seeing better performance in the latter half due to patient out-of-pocket expenses resetting at the beginning of the year [46][47] Other Important Information - The company has entered into a $4 million accounts receivable line of credit with Silicon Valley Bank to support operations [21] - The company expects to file a new shelf registration statement shortly to maintain a valid registration for future offerings [21] Q&A Session Summary Question: Confidence around increasing manufacturing capacity - Management indicated plans to expand capacity beyond 80 units per month by Q4 and potentially add a second shift next year [28] Question: Goals for the O&P channel team - The focus is on building relationships and training clinicians this year, with material revenue expected to build in 2025 [30] Question: Gross margins outlook - Management views 70% as a good baseline for gross margins, with potential for expansion as more Medicare Advantage plans reimburse at the Medicare allowable rate [34] Question: Impact of political advertising on pipeline - Management acknowledged that political advertising could create competition for patient attention in Q3 and Q4, but they are increasing advertising spend to mitigate this [39] Question: Increasing marketing without impacting bottom line - Management is balancing increased marketing spend with the goal of achieving operating cash flow breakeven in Q4 while ensuring revenue growth in 2025 [44]

INVESTOR PRESENTATION AUGUST 2024 Paul R. Gudonis, Chairman and CEO David Henry, CFO Conquering Upper Limb Paralysis with Wearable Medical Robotics NYSE American: MYO 1 NYSE American: MYO Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Legal Disclaimer This presentation contains forward-looking statements regarding the trading of the Company's common stock on the NYSE American, the Company's plans for the use of proceeds and advancing its product li ...

Revenue Growth - Product revenue for the three months ended June 30, 2024, increased by approximately $3,277,100, or 77%, compared to the same period in 2023, reaching $7,520,767[84] - Total revenue for the six months ended June 30, 2024, increased by approximately $1,869,900, or 20%, compared to the same period in 2023, totaling $11,275,156[84] - Revenues from Medicare Part B beneficiaries represented 47% and 35% of product revenues for the three and six months ended June 30, 2024, respectively[80] Gross Margin - Gross margin for product revenue was 70.8% for the three months ended June 30, 2024, compared to 60.5% for the same period in 2023[85] Operating Expenses - Operating expenses for the three months ended June 30, 2024, totaled $6,440,576, an increase of 20% compared to $5,384,062 for the same period in 2023[87] - SC&M expenses rose by approximately $505,200 (22%) and $836,500 (19%) during the three and six months ended June 30, 2024, respectively, driven by increased headcount and higher travel costs[90] - G&A expenses increased by approximately $108,300 (4%) and $507,000 (10%) for the three and six months ended June 30, 2024, respectively, mainly due to higher payroll costs and increased legal fees[92] Research and Development - Research and development expenses increased by 79% to $1,007,224 for the three months ended June 30, 2024, compared to $564,235 for the same period in 2023[87] - R&D expenses increased by approximately $443,000 (79%) and $922,200 (89%) for the three and six months ended June 30, 2024, compared to the same periods in 2023, primarily due to higher payroll costs[89] Net Loss and Cash Flow - The company reported a net loss of $1,121,607 for the three months ended June 30, 2024, compared to a net loss of $1,014,150 for the same period in 2023[97] - The company used approximately $5.2 million in cash for operating activities during the six months ended June 30, 2024, compared to $2.1 million for the same period in 2023[101] - The company anticipates continued net losses and negative cash flows as it expands sales and marketing efforts and invests in product development[81] Financial Position - As of June 30, 2024, the company had cash and cash equivalents of approximately $5.8 million and total working capital of approximately $8.7 million[98] - The company generated net proceeds of approximately $5.4 million from a registered direct equity offering completed in January 2024[99] - The company entered into a Loan and Security Agreement with Silicon Valley Bank, allowing it to borrow up to $4.0 million against eligible accounts receivable[99] Future Plans - The company plans to hire 50 to 60 people through the second quarter of 2024 to increase clinical, reimbursement, and manufacturing capacity[78] - The company plans to increase clinical, reimbursement, and manufacturing capacity, aiming for cash flow breakeven by the fourth quarter of 2024[101] Regulatory and Market Information - The Centers for Medicare and Medicaid Services (CMS) published final average payment determinations of approximately $33,500 for MyoPro Motion W and $65,900 for MyoPro Motion G, effective April 1, 2024[79] - The joint venture in China has a minimum purchase commitment of $10.75 million for MyoPro Control System units over the next ten years[77] - Recent accounting standards are detailed in Note 3 of the unaudited condensed consolidated financial statements[106] - Item 3 regarding quantitative and qualitative disclosures about market risk is not applicable as the company is classified as a smaller reporting company[107]

Revenue Performance - Record revenue of $7.5 million for Q2 2024, up 26% year-over-year, with product revenue increasing 77%[1] - Year-to-date revenue for 2024 was $11.3 million, up 20% compared to the same period in 2023[3] - The company expects Q3 2024 revenue to be in the range of $8.0 million to $8.5 million, with a full-year revenue expectation of $28 million to $30 million[8] - Product revenue for the three months ended June 30, 2024, was $7,520,767, a 77% increase from $4,243,624 in the same period of 2023[15] Patient Pipeline and Authorizations - 213 MyoPro authorizations and orders received, representing a 70% increase compared to Q2 2023[1] - Patient pipeline reached 1,179 candidates, up 22% year-over-year, with 550 new candidates added in Q2 2024, a 35% increase[1] - Cost per pipeline add decreased to $1,545, down 26% compared to Q2 2023[5] Financial Metrics - Gross margin for Q2 2024 was 70.8%, down 100 basis points from 71.8% in Q2 2023, while gross margin on product revenues increased by 1,030 basis points[1][4] - Gross profit for the six months ended June 30, 2024, was $7,624,555, compared to $6,588,658 for the same period in 2023, reflecting a 15.8% increase[15] - Operating expenses for Q2 2024 were $6.4 million, a 20% increase compared to Q2 2023, driven by higher payroll expenses[5] - Operating expenses for the three months ended June 30, 2024, totaled $6,440,576, up from $5,384,063 in the same period of 2023, representing a 19.6% increase[15] Losses and Cash Flow - Year-to-date operating loss was $5.0 million, compared to a loss of $3.8 million for the same period in 2023[6] - Net loss for the six months ended June 30, 2024, was $4,957,239, compared to a net loss of $3,658,445 for the same period in 2023, indicating a 35.4% increase in losses[17] - Net cash used in operating activities for the six months ended June 30, 2024, was $5,161,488, compared to $2,102,213 for the same period in 2023, indicating a significant increase in cash outflow[17] - Adjusted EBITDA for the six months ended June 30, 2024, was $(4,709,773), compared to $(3,227,923) for the same period in 2023, showing a worsening of 46%[18] Cash Position and Assets - Cash position as of June 30, 2024, was $9.0 million, with cash used in operating activities of $1.9 million for Q2 2024[9] - Cash and cash equivalents at the end of June 30, 2024, were $5,846,100, down from $6,871,306 at the end of December 31, 2023[16] - Total assets increased to $16,190,381 as of June 30, 2024, compared to $14,581,568 as of December 31, 2023, marking an 11% growth[16] - Total stockholders' equity rose to $9,677,711 as of June 30, 2024, from $8,989,350 at the end of December 31, 2023, reflecting a 7.7% increase[16] Shareholder Information - The weighted average number of common shares outstanding increased to 37,368,488 for the three months ended June 30, 2024, from 27,992,928 in the same period of 2023[15]

Exhibit 99.1 Myomo Reports First Quarter 2024 Financial Results Record 275 patients in backlog, includes 180 authorizations and orders in Q1, up 48% over the prior year Record 493 MyoPro candidates added to the pipeline in Q1 Revenue of $3.8 million, up 9% over the prior year Conference call begins at 4:30 p.m. Eastern time today BOSTON (May 8, 2024) – Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38109 MYOMO, INC. (Exact name of Registrant as Specified in its Charter) Delaware 47-0944526 (State or Other Jurisdiction of ( ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 (State or other jurisdiction of incorporation or organization) 137 Portland St., 4 Floor, Boston, Massachusetts 02114 (Address of principal executive offices) (Zip Code) th Delaware 47-0944526 (I.R.S. Employer Identification No.) Registrant's telephone number, including ...

Myomo, Inc. (NYSE:MYO) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Kim Golodetz - Investor Relations, LHA Paul Gudonis - Chairman & Chief Executive Officer Dave Henry - Chief Financial Officer Conference Call Participants Anthony Vendetti - Maxim Group Edward Woo - Ascendant Capital Ben Haynor - Alliance Global Partners Operator Hello, and welcome to the Myomo Fourth Quarter 2023 Earnings Call. All participants will be in a listen-only mode. [Operator Instructions] Please ...